The more favorable pharmacodynamic parameters of the 750 mg dose may lead to faster eradication of the pathogen which may produce faster resolution of symptoms, thereby allowing an earlier switch from intravenous to oral therapy and earlier hospital discharge. The more rapid eradication of the pathogen allows shorter-course therapy to be considered, which has several potential clinical and economic advantages.